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Abstract
Background: Nocturia is a common urinary symptom of multiple sclerosis (MS) which can affect quality of life
(QoL) adversely. Melatonin is a hormone known to regulate circadian rhythm and reduce smooth muscle activity
such as in the bladder. There is limited evidence supporting use of melatonin to alleviate urinary frequency at night
in the treatment of nocturia. The aim of this study was to evaluate the effect of melatonin on the mean number of
nocturia episodes per night in patients with MS.
Methods: A randomized, double blind, placebo controlled crossover trial was conducted. 34 patients with nocturia
secondary to multiple sclerosis underwent a 4-day pre-treatment monitoring phase. The patients were randomized
to receive either 2 mg per night (taken at bedtime) of capsulated sustained-release melatonin (Circadin®) or 1 placebo
capsule for 6 weeks followed by a crossover to the other regimen for an additional 6 weeks after a 1-month washout
period.
Results: From the 26 patients who completed the study, there was no significant difference observed in the signs or
symptoms of nocturia when taking 2 mg melatonin compared to placebo. The primary outcome measure, mean
number of nocturia episodes on bladder diaries, was 1.8/night at baseline, and 1.4/night on melatonin, compared with
1.6 for placebo (Medians 1.70, 1.50, and 1.30 respectively, p = 0.85). There was also no significant difference seen in
LUTS, QoL and sleep quality when taking melatonin. No significant safety concerns arose.
Conclusions: This small study suggests that a low dose of melatonin taken at bedtime may be ineffective therapy for
nocturia in MS.
Trial registration: (EudraCT reference) 2012–00418321 registered: 25/01/13. ISRCTN Registry: ISRCTN38687869.
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Background
Nocturia is the complaint that the individual has to wake
at night one or more times to void [1]. It can result from
a range of factors, including behavioural influences, sleep
disturbances, lower urinary tract dysfunction and altered
fluid or salt homeostasis. Nocturia is prevalent in the
general population and is known to increase in severity
with age. 77% of people aged 60 and above experience some
degree of nocturia with no difference seen between men
and women [2]. Nocturia impacts greatly on quality of life
(QoL), potentially due to fatigue, cognitive dysfunction and
disturbed emotional health [3]. Furthermore, severe noc-
turia may be associated with cardiovascular disease, auto-
nomic disease, obstructive sleep apnoea and chronic kidney
disease [4], and potentially a higher risk of mortality
[5]. A very high proportion of MS patients have lower
urinary tract symptoms (LUTS) [6]. LUTS are a sub-
stantial problem in MS, and nocturia is a particularly
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prominent symptom with substantial detrimental im-
pact on QoL [7].
Current treatments for nocturia include managing fluid
intake, timed diuretics, desmopressin, antimuscarinic drugs,
bedtime sedatives and miscellaneous compounds [8]. Des-
mopressin is indicated for treatment of nocturia in MS [9].
However, desmopressin can cause hyponatraemia [10]
and has been associated with hyponatraemic convulsions
[11, 12]. Indeed, it is recommended that tri-cyclic antide-
pressants (commonly used in MS patients) are avoided
when using Desmopressin to reduce the risk of hyponatrae-
mia (British National Formulary). This can also potentially
be an issue with diuretics. Antimuscarinics are known to
cause dry mouth, constipation, swallowing difficulty and
confusion. Patients taking sedatives can experience hang-
over sedation, while elderly subjects are at risk of cognitive
impairment [13]. These side effects and poor efficacy mean
that clinicians are sometimes reluctant to initiate treatment
for nocturia.
Melatonin (N-acetyl-5-methoxytryptamine) is a hor-
mone secreted primarily at night by the pineal gland. It
regulates circadian rhythms and reduces smooth muscle
spontaneous activity, including that found in the bladder
[14]. Melatonin tablets taken before bedtime may reduce
nocturia in a subgroup of patients with benign prostate
enlargement [15]. In elderly patients with nocturia, levels
of severity and QoL improve with melatonin use [16]. In
MS, sleep quality is commonly reduced as a consequence
of a wide range of sleep abnormalities, of which nocturia
is only one example. In MS there can be an impairment of
endogenous melatonin secretion [17, 18], and administra-
tion of oral melatonin improves reduced sleep quality in
MS patients [19].
We hypothesised that bedtime administration of a
melatonin sustained-release tablet will improve clinical
nocturia in patients with MS. We previously published
the protocol of the “Melatonin for nocturia in MS
(MeNiMS)” study to evaluate this hypothesis [20], and
the current study reports the findings. We chose a low
dose of 2 mg, as melatonin levels negatively correlate
with multiple sclerosis activity in humans, and alterations
in endogenous melatonin have been proposed potentially
to affect MS relapses [21]. The primary aim was to evalu-
ate the effect of melatonin on mean number of nocturia
episodes per night in MS patients. The secondary aims
included: 1) improvement in QoL, 2) safety, 3) LUTS, 4)
sleep quality and 5) total voided (urinated) volume and
mean volume per void. A qualitative study was also in-
cluded, which will be reported separately.
Methods
The detailed study protocol has previously been pub-
lished [20]. In brief, male and female patients aged ≥18
were recruited at Southmead Hospital, Bristol, UK. Each
patient had a confirmed neurological diagnosis of MS as
per the 2010 McDonald MS Criteria [22]. They also
reported at least one episode of nocturia every night on
the International Consultation on Incontinence Ques-
tionnaires (ICIQ) Nocturia questionnaire (ICIQ-N [23]).
Patients were excluded if they had (i) an indwelling urin-
ary catheter; (ii) used desmopressin or investigational
medications in the month preceding randomization; (iii)
taken antimuscarinic or diuretic medication, unless used
long-term prior to study (> 3 months) and continued
throughout the study; (iv) taken melatonin on prescription
or purchased; (v) used “sleeping tablets” on prescription
or purchased; (vi) diabetes mellitus/diabetes insipidus;
and (vii) or if they were pregnant at screening, or of
child-bearing potential and unwilling to use contracep-
tion. Dipstick urinalysis to exclude urinary tract infec-
tion was undertaken at screening. The U.K. National
Research Ethics Service Committee South West – Exeter
approved the study protocol (REC reference number: 12/
SW/0322).
This was a randomized, double blind, placebo controlled
crossover trial with two groups (Fig. 1). Following an initial
four-day pre-treatment monitoring phase, the treatment
phases were 2 mg per night of capsulated sustained-release
melatonin (‘Circadin’) or an identical placebo capsule per
night for 6 weeks each, separated by a 4 week washout
period. Patients were allocated double-blind via a website
(http://www.randomization.com) to group AB or BA, with
unblinding undertaken following database lock and analysis
(A = placebo, B =melatonin).
The primary outcome was reduction in nocturia episodes
per night, derived from the ICIQ bladder diary (ICIQ-BD)
[24]. Secondary outcomes included; 1. Subjective severity,
using the ICIQ tools on nocturia (ICIQ-N) and nocturia
quality of life (ICIQ-NQoL) [25]. 2. MS quality of life,
assessed with the MSQoL scale. 3. LUTS, assessed with the
ICIQ-MLUTS and ICIQ-FLUTS for males and females
respectively. 4. Sleep quality; measured with the Pittsburgh
Sleep Quality Index (PSQI). 5. Safety, based on adverse
event reporting and Expanded Disability Status Scale
(EDSS) score [26]. Outcome measures were completed
at baseline and at the end of each treatment phase. Ad-
verse event reporting was undertaken throughout, and
followed up until resolution or for 3 months [20].
Statistical analysis
We calculated that for a two-sided test, using standard
levels of statistical significance (alpha = 0.05), a sample
size of n = 21 complete data sets would have 80% power
to detect a medium to large effect size (Cohen’s d = 0.65)
with 80% power, and a sample size of n = 34 would be
needed for a medium effect size (Cohen’s d = 0.5) [20].
The balanced two group, two period, two sequence,
double-blind, randomised crossover design with wash-out
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period comparing treatment to control, ranks highly in
the hierarchy of designs. The analyses of the resultant data
under this AB/BA design may proceed using nonparamet-
ric (Mann-Whitney-Wilcoxon U) two-sample statistical
techniques which assess for carryover effects, period
effects, and treatment effect accounting for any period
effects using independent samples designs [27] or using
paired samples in the absence of period and carryover
effects. Treatment effect sizes have been quantified and
converted to Cohen’s d. For Cohen’s standardized statistic,
d = 0 indicates the absence of an effect. For statistically
significant effects, some broad and cautious threshold
guidance to aid interpretation is for, 0 < d < 0.1 to indi-
cate a trivial effect, 0.1 < d < 0.3 to indicate a small
effect, 0.3 < d < 0.5 to indicate a moderate effect, 0.5 < d <
0.8 a medium size effect, 0.8 < d < 1.3 a large effect, and
d > 1.3 a very large effect [28]. A missing data analysis was
also performed on the primary outcome measure to assess
sensitivity of statistical conclusions to missingness. This
analysis indicated any missing data to be consistent with
being missing completely at random (MCAR). Multiple
Imputation by Chained Equations (MICE) [29] with 1000
imputed data sets was performed. These imputed analyses
faithfully reproduced the findings from the observed sam-
ple data and for brevity of exposition, and to avoid redun-
dancy, are not reported in full.
Results
In total 13 men and 18 women of mean age 54.8 years
(range 34–69) were randomised. Five patients had Primary
Progressive MS, 15 patients had Secondary Progressive
MS and 11 patients had Relapsing Remitting MS (RRMS).
Fig. 1 Study flow chart
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Five of the 11 with RRMS were taking disease modifying
therapy at the time of the trial (one interferon beta-1a,
two fingolomid and two dimethyl fumarate). Mean EDSS
was 4.2 (median 4.0, range 1.5 to 8.0). Five patients
withdrew from the trial (Fig. 1). Reasons for withdrawal
were; adverse events (three patients), new-onset unre-
lated health problems (one patient) and logistic burden
(one patient). Mean nocturia severity at baseline from the
bladder diary was 1.78 episodes/night and self-reported
mean ICIQ symptom score for nocturia was 1.80 epi-
sodes/night (range 1–3).
The effects of 2 mg melatonin and placebo on bladder
diary parameters are shown in Table 1. There was no
significant change seen with melatonin for the primary
outcome measure, the number of nocturnal episodes per
night. “Objective” nocturia was 1.4/ night for melatonin,
compared with 1.6 for placebo (U = 43, p = 0.85). Average
nocturnal output and nocturnal polyuria index (NPI) were
also not significantly altered. Effects on patient-reported
LUTS are shown in Table 2. For patient-reported (subject-
ive) nocturia, the number of episodes per night after 6
weeks of melatonin was 3.3, compared with 3.2 with pla-
cebo. Overall scores and individual LUTS were not signifi-
cantly different with melatonin compared with placebo.
Secondary end points looking at QoL also revealed
that melatonin did not significantly affect outcomes. The
ICIQ-NQoL questionnaire mean totals were 22.1 for
melatonin, compared with 23.6 for placebo (U = 41.5,
p = 0.34; Table 3). For the MSQoL scale (Table 4), there
was no significant change between melatonin and pla-
cebo in most of the domains, except for physical overall
score (50.9 vs. 47.9, respectively, median 48.5 vs 44.0,
U = 26, p = 0.02), role limitations due to physical prob-
lems (39.1 vs. 33.3, median 25 vs 12.5, U = 29, p = 0.02)
and pain score (62.7 vs. 70.6, median 70 vs. 78, U = 34.5,
p = 0.03). In the PSQI (Table 5), the mean scores were
8.1 and 8.7 for melatonin and placebo respectively (me-
dian 8.0 vs. 9.0 respectively, U = 56.5, p = 0.89).
In all analyses there was little evidence of any carryover
effects (i.e. no evidence of period by treatment interaction
effects, consistent with a sufficiently large washout period).
In addition, the given conclusions for treatment effects are
replicated if differences are examined as paired differences
using the non-parametric Wilcoxon signed rank test.
Safety
EDSS data is given in Table 6. Overall, there was no dif-
ference in EDSS while taking melatonin or placebo;
mean score was 4.4 for placebo and 4.7 for melatonin
(medians 4.0 and 4.0). Four patients reported worsening
symptoms of MS during the study, of which two were
taking melatonin at the time. One experienced two sep-
arate episodes, once whilst taking melatonin and once
whilst taking placebo. One patient experienced Uhthoff ’s
phenomenon, a worsening of neurological condition re-
lated to MS, while taking melatonin.
Adverse event reporting most commonly identified
urinary tract infection (UTI), which affected seven par-
ticipants. Four of these were prior to receipt of study
medication. Three UTIs were found after randomisation.
One was on treatment phase 1 and was receiving mela-
tonin. Another had completed treatment phase 2 (pla-
cebo). One participant was found to have a UTI after
the post drug wash out phase for melatonin.
Two patients experienced faecal urgency; both were
no longer taking study medication at the time of onset,
and both had been taking placebo.
Two participants experienced lassitude and anergia.
One was withdrawn by the clinician, and was found to
have been taking placebo. The other had already com-
pleted the study, and had been taking melatonin as the
most recent study medication.
One patient experienced severe dizziness, and was un-
blinded and was found to have been taking placebo; this
patient was withdrawn from the study. A further patient
reported abdominal pain (a reported potential side effect
of Melatonin), and was withdrawn by the clinician with-
out unblinding; subsequently the patient was found to
have been taking placebo.
Two patients reported chest infections, one taking pla-
cebo and the other melatonin. One of these patients went
on to report a further three adverse events of pain in fin-
gers, knees and shoulder, which all occurred whilst taking
placebo.
Table 1 Median and range for average number of nocturia episodes, voided output, and NPI by treatment with treatment p-value
and standardized effect size, d
Measure Treatment
Baseline A: Placebo B: Melatonin p d
Median Range Median Range Median Range
Average Nocturia Episodes 1.70 1–3 1.50 0–3 1.30 0–3.3 0.618 0.136
Average nocturnal urine output (mls) 741 310–1416 651 300–1933 667 200–1100 0.939 0.020
24-h voided volume (mls) 2125 1200–4000 2213 1250–3900 2000 881–3600 0.254 0.314
Nocturnal Polyuria Index NPI 0.32 0.15–0.71 0.33 0.17–0.56 0.32 0.15–0.60 0.849 0.052
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One patient experienced abdominal pain resulting in
emergency department review, where cholecystitis was
diagnosed. She also reported shingles and reduced mo-
bility in separate adverse events. She had been taking the
placebo on all of these occasions. One patient reported a
probable olecranon bursitis while taking placebo. Colds
and an ear infection were reported by two patients; both
were taking placebo.
Discussion
Nocturia is a prominent symptom with substantial detri-
mental impact on quality of life in MS, especially in light
of the range of factors affecting sleep quality in these
patients. Ordinarily, there should be a reduction in urine
production rate during sleep. Endogenous melatonin is a
key contributor in circadian control, and disruption of
melatonin is a feature in sleep disturbance in MS [30].
We surmised that beneficial effects may result indirectly
by improved sleep quality, and perhaps directly by some
restoration of the normal circadian reduction in urine
production at night, and reduced bladder smooth muscle
activity. A potential impact of giving supplementary mela-
tonin orally as regulator of circadian rhythms in restoring
some measure of circadian control [31] could be beneficial
in the proposed context. In reality, the effect of melatonin
in the current study did not identify any reduction in noc-
turia (either objectively or subjectively). The bladder diary
was the main outcome assessment, and during the active
treatment phase there was no reduction in nocturia epi-
sodes or overall nocturnal urine production.
For the PSQI, the mean scores at the end of the treat-
ment phase were 8.1 for melatonin and 8.7 for placebo.
This difference was statistically significant, and seems to
indicate worse function with melatonin, but the difference
is modest and unlikely to be clinically significant. We also
evaluated other aspects of the patient’s health and QoL.
For the MSQoL, there was no significant change between
melatonin and placebo in most of the domains, except
that small statistically significant differences were evident
in the physical overall score, role limitations due to phys-
ical problems, and pain score. It is unclear that this was a
definite consequence of melatonin action.
Symptom scores were a key secondary measure, and
again melatonin did not appear to have any effect on
nocturia specifically or LUTS in general. Nocturia-specific
quality of life did not show any evident improvement.
Nocturia has a multifactorial pathophysiology, which po-
tentially could mean that melatonin might have effect in
some individuals and not others, and this was considered
to explain the finding of a responder group in a previous
study which examined melatonin use for treatment of
nocturia in men with benign prostate enlargement [15].
However, there did not seem to be any evident responder
group in the current study.
The lack of evident difference between melatonin and
placebo may reflect the pragmatic approach taken in the
study. Diabetes mellitus and diabetes insipidus were
excluded, but otherwise inclusive criteria were used for
study recruitment. This pragmatic approach was taken
to reflect the utility of a therapy which could be applied
to the majority of patients in the general healthcare
context, without having to undertake too much clinical
assessment. The fact that we did not identify benefit
could reflect the wide range of potential co-morbidity in
Table 2 Median and range of the grouped sub-scores (Voiding and Incontinence) and the individual symptom scores for nocturia,
urgency and frequency from the ICIQ LUTS questionnaires (MLUTS and FLUTS for males and females respectively) by treatment, with
p-values and standardized effect size, d
Measure Treatment
A: Placebo B: Melatonin p d
Median Range Median Range
Voiding sub-score 4.0 0–12 2.0 0–12 0.096 0.492
Incontinence (Storage) sub-score 3.0 0–9 3.0 0–12 0.107 0.450
Nocturia 2.0 1–3 2.0 1–3 0.892 0.037
Urgency 2.0 0–3 2.0 1–4 0.772 0.079
Table 3 Median and range for ICIQ NQol by treatment with p-value and standardized effect size, d
Measure Treatment
A: Placebo B: Melatonin p d
Median Range Median Range
Overall score 25.0 8–35 20.0 8–42 0.341 0.261
Overall interference 5.0 0–9 4.0 0–9 0.444 0.209
Sleep/Energy sub-score 11.0 3–19 10.0 3–18 0.549 0.164
Bother/Concern sub-score 9.5 4–21 9.0 3–16 0.288 0.292
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MS, indicating that it is likely that assessment of specific
underlying mechanisms probably is needed to under-
stand nocturia in MS. A low dose of melatonin was
chosen (2 mg), because at the time the study was designed
there was discussion that melatonin could potentially con-
tribute to deterioration in MS severity through effects on
immune function [32]. Based on the results, it seems that
this low dose was insufficient for nocturia therapy, even
though it is a standard dose for treating sleep disorders in a
wider population. Some studies have used higher doses of
melatonin in an MS population, demonstrating improved
sleep quality [19]. Recent literature does not identify detri-
mental effect of melatonin on MS severity, and alternative
hypotheses have been promulgated regarding a potential
beneficial effect. We did not measure endogenous mela-
tonin production, or effective serum melatonin levels on
treated patients, so we are unable to state whether serum
levels of the hormone reached therapeutic levels in our
study population.
The inclusion of a placebo group is an essential part of
LUTS investigation, since placebo responses are noted
to be rather big generally [33]. In the current study, the
placebo response seen in the bladder diaries and symp-
tom scores was modest. Undertaking observations such
as bladder diaries is considered a potential factor that
could influence patient behaviour, since completing a
bladder diary shows to a patient when they are generat-
ing a high urine output, which can feed back on their
behaviour. This was not a particular observation in the
current study, where the baseline 24 h voided volume
was 2.2 L, and was similar during the treatment phases
(2.2 L for placebo, and 2.0 L per 24 h for melatonin, me-
dians 2.1 L, 2.2 L, and 2.0 L respectively). The nocturnal
polyuria index was unchanged (median 0.32, 0.33, 0.32
Table 4 Median and range for MSQoL by treatment, with p-value and standardized effect size, d
Measure Treatment
A: Placebo B: Melatonin p d
Median Range Median Range
Mental Overall Score 68.0 16–92 75.0 28–92 0.110 0.446
Physical Overall Score 44.0 17–89 48.5 21–90 0.023 0.651
Energy Score 30.0 0–76 36.0 0–84 0.212 0.347
Emotional Wellbeing 68.0 32–100 72.0 32–100 0.961 0.013
Physical Health 45.0 5–100 40.0 5–100 0.701 0.105
Role limitations due to physical problems 12.5 0–100 25.0 0–100 0.015 0.701
Role limitations due to emotional problems 100 0–100 100 0–100 0.580 0.151
Health Perceptions 42.5 5–85 45.0 0–80 0.396 0.233
Social Function 67.0 25–100 67.0 0–100 0.603 0.142
Cognitive Function 67.0 0–100 73.0 0–100 0.884 0.040
Health Distress 60.0 15–90 60.0 0–100 0.862 0.036
Change in Health 25.0 0–50 50.0 25–100 0.647 0.125
Quality of Life 55.0 27–95 63.0 0–90 0.130 0.421
Pain Score 78.0 0–100 70.0 0–100 0.029 0.622
Table 5 Median and range for PSQI by treatment, with p-value and standardized effect size, d
Measure Treatment
A: Placebo B: Melatonin p D
Median Range Median Range
Overall Score 9.0 2–13 8.0 2–16 0.893 0.036
Sleep Disturbances 2.0 1–3 2.0 1–3 0.092 0.471
Sleep Medication 0.0 0–0 0.0 0–3 0.228 0.333
Sleep Duration 1.0 0–3 1.0 0–3 0.663 0.119
Sleep Latency 1.0 0–5 1.0 0–3 0.927 0.025
Sleep Quality 1.0 0–3 1.0 0–3 0.922 0.027
Daytime Dysfunction 1.0 0–3 1.0 1–3 0.141 0.410
Habitual Sleep Efficiency 2.0 0–3 1.0 0–3 0.114 0.440
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for baseline, placebo and melatonin respectively). A
small reduction in median nocturnal urine output was
seen (baseline 741 mL, placebo 651 mL, and melatonin
667 mL), but this was not statistically significant. It did
not yield a significant change in nocturia episodes (median
1.70, 1.50 and 1.30 respectively).
There was no clear adverse safety signal. No adverse
events appeared to have any clear link to the melatonin
therapy on a consistent basis. UTIs were reported, and
two episodes of faecal urgency. Single presentations with
Uhthoff ’s phenomenon, feeling drained, cold hands, pro-
found somnolence, and others were also described. The
qualitative interviews also identified that fatigue was a
key feature. The individual with Uhthoff ’s phenomenon
explains the difference in the visual domain on the EDSS
scores, which were otherwise not significantly different
for the melatonin and placebo phases.
Conclusions
In summary, a low dose of melatonin taken at bedtime
may be an ineffective therapy for nocturia in MS, studying
an adult population with nocturia once per night or more
often. A different dose regime of melatonin or recruitment
selection criteria would need to considered to ascertain
whether melatonin could influence nocturia in MS.
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